暂无摘要。

暂无摘要。

The U.S. Food and Drug Administration approved romosozumab as a new osteoporosis drug in April 2019. Marketed under the brand name Evenity (Amgen, Thousand Oaks, CA), it is a sclerostin inhibitor that promotes new bone formation. It is the first in its drug class to work by increasing bone formation and also preventing bone resorption. It has been approved for use in postmenopausal women at greater risk for bone fracture. Romosozumab is administered once monthly in injection form for 12 consecutive months.

暂无摘要。